Research Library · Metabolic
What is Cagrilintide?
Cagrilintide (Cagrilintide) is a research compound studied in metabolic. A long-acting amylin analog. Studied as a satiety-signaling adjunct to GLP-1 agonists for compound weight-management and appetite-regulation research.
Overview
Cagrilintide is a once-weekly amylin analog originally developed as a companion to semaglutide. Amylin is co-secreted with insulin by pancreatic β-cells and signals satiety through the area postrema — a mechanism parallel to but distinct from GLP-1. Why the dual-mechanism matters: GLP-1 agonists act on hypothalamic nuclei; amylin acts on the brainstem. Published research pairing the two shows additive — sometimes synergistic — effects on food intake and body-weight endpoints. IF the research question is maximal appetite suppression with complementary pathways, THEN the amylin + GLP-1 pairing (CagriSema-style) is where the current metabolic literature is concentrated. SO Cagrilintide belongs in any study comparing mono- versus dual-agonist weight-regulation. Lyophilized, ≥99% purity, CoA-verified.
Research areas
Amylin receptor signaling
<p>Activates amylin receptors (CTR + RAMP1/3) in the area postrema. Slows gastric emptying, suppresses glucagon post-prandially, and reduces food intake via brainstem signaling.</p>
Combination with GLP-1
<p>Phase-2 trials of Cagrilintide + Semaglutide (the CagriSema combination) report weight-loss outcomes exceeding either agonist alone. Most-studied combo in modern obesity pharmacology.</p>
Half-life & dosing
<p>Fatty-acid conjugation extends plasma half-life to ~7 days, enabling once-weekly administration. Most human protocols use a slow-titration schedule to manage gastrointestinal adaptation.</p>
Storage
<p>Lyophilized powder stable at 2–8°C. Reconstituted solution retains potency for 30+ days under refrigeration.</p>
Published research
- CagriSema Reduces Blood Pressure in Adults With…
PMID 41328546 — PubMed
- a multicentre, randomised, active-controlled, phase 3a trial
PMID 42009015 — PubMed
- Cagrilintide-Semaglutide in Adults with Overweight or…
PMID 40544432 — PubMed
- Coadministered Cagrilintide and Semaglutide in Adults…
PMID 40544433 — PubMed
- Efficacy and Safety of Cagrilintide and Cagrisema Versus…
PMID 41834765 — PubMed
- Efficacy and safety of once-weekly cagrilintide-semaglutide…
PMID 42251860 — PubMed
Storage & handling
Lyophilized Cagrilintideis stored at –20 °C protected from light. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 30 days for maximum stability.
Frequently asked questions
- What is Cagrilintide?
- Cagrilintide (Cagrilintide) is a research compound studied in the area of metabolic. A long-acting amylin analog. Studied as a satiety-signaling adjunct to GLP-1 agonists for compound weight-management and appetite-regulation research.
- What is the CAS number of Cagrilintide?
- The CAS registry number of Cagrilintide is 1415456-99-3.
- How should Cagrilintide be stored?
- Lyophilized Cagrilintide should be stored at –20 °C protected from light. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 30 days for maximum stability.
- How is the purity of Cagrilintide verified?
- Every Woosh Labs batch of Cagrilintide is independently tested by third-party HPLC and mass spectrometry, with a batch-specific Certificate of Analysis published verifying ≥99% purity.
- Is Cagrilintide for human use?
- No. Cagrilintide sold by Woosh Labs is strictly for in-vitro laboratory research by qualified professionals. It is not for human or veterinary use of any kind.
This page is for informational purposes for qualified researchers. All Woosh Labs products are for laboratory research use only and are not intended for human or veterinary use. Nothing here is medical advice or a claim of therapeutic effect.
